| Literature DB >> 35401422 |
Jia-Kai He1,2, Bao-Hui Jia2, Yu Wang1, Shao-Yuan Li1, Bin Zhao1,3, Zeng-Guang Zhou4, Yan-Zhi Bi5, Mo-Zheng Wu1, Liang Li1, Jin-Ling Zhang1, Ji-Liang Fang6, Pei-Jing Rong1.
Abstract
Objectives: Transcutaneous auricular vagus nerve stimulation (taVNS) has been reported to be effective for chronic insomnia (CI). However, the appropriate population for taVNS to treat insomnia is unclear.Entities:
Keywords: biomarkers; chronic insomnia; functional magnetic resonance imaging (fMRI); neuromodulation; prefrontal cortex; transcutaneous auricular vagus nerve stimulation
Year: 2022 PMID: 35401422 PMCID: PMC8987020 DOI: 10.3389/fneur.2022.827749
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Sample characteristics of the participants.
|
|
|
|
|
|
|---|---|---|---|---|
| Age (year) | 42.50 ± 15.42 | 43.5 ± 11.23 | −0.278 | 0.781 |
| Sex (M/F) | 8/12 | 6/12 | 0.181 | 0.671 |
| Education (year) | 12.20 ± 4.62 | 12.83 ± 6.24 | −0.179 | 0.858 |
Z, Wilcoxon rank testing; χ.
Figure 1(A) The electrodes were attached to the surface of cymba conchae. (B) The stimulating place of taVNS. RS-fMRI, rest-state functional Magnetic Resonance Imaging; taVNS, Transcutaneous Auricular Vagus Nerve Stimulation.
Figure 2Changes of fMRI induced by instant taVNS were measured before and after the first treatment on the two groups. Clinical scales for patients were assessed before and after the 4 weeks' taVNS treatment.
Improvement of PSQI and FFS after 4-weeks taVNS treatment ( ± s).
|
|
|
|
|
|
|---|---|---|---|---|
| PSQI ( | 12.7 ± 3.715 | 9.75 ± 4.278 | 3.337 | 0.003 |
| FFS ( | 14.5 ± 5.92 | 11.5 ± 4.136 | 2.860 | 0.010 |
p < 0.05;
p < 0.01; Z, Wilcoxon rank testing; PSQI, Pittsburgh Sleep Quality Index; FFS, Flinders Fatigue Scale; Change at week 4 to baseline mean (95% CI).
Figure 3(A) Different voxel based analyses showed similar up- regulated area in left dorsolateral prefrontal cortex. (B) Changes of different voxel based analyses before and after taVNS. (C) ALFF analysis showed taVNS aroused higher activation in the CI group than in the HC group. (D) The FC between the up- regulated dlPFC and bilateral dorsomedial prefrontal cortex decreased after taVNS. (E) Correlations between the clinical scales' scores and the fMRI values. PSQI, Pittsburgh Sleep Quality Index; FFS, Flinders Fatigue Scale; ALFF, amplitude of low frequency fluctuation; fALFF, Fractional ALFF; ReHo, Regional homogeneity; FC, Functional connectivity; 0w, before taVNS treatment; 4w, after 4 week taVNS treatment; Relief Rate, The remission rate was defined as the difference in scale scores before and after treatment divided by the scale scores before treatment. *p < 0.05; **p < 0.01.
Brain changes after the first taVNS session (N = 20).
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
|
|
|
| |||||
| ALFF | Frontal_Mid_L | 10/46 | 37 | −39 | 36 | 21 | 7.791 |
| fALFF | Frontal_Mid_L | 10/46 | 26 | −39 | 39 | 21 | 8.305 |
| ReHo | Frontal_Mid_L | 10/45/46 | 71 | −39 | 39 | 21 | 7.364 |
| FC | Frontal_Sup_ | 9/10 | 28 | 3 | 57 | 21 | −5.143 |
ALFF, Low frequency fluctuation in the left dorsolateral prefrontal lobe; fALFF, Fractional amplitude of low frequency fluctuation in the left dorsolateral prefrontal lobe; ReHo, Regional homogeneity in the left dorsolateral prefrontal lobe; FC, Functional connectivity between left dorsolateral prefrontal and medial prefrontal lobe; AAL, Anatomical Automatic Labeling; MNI, Montreal Neurological Institute; BA, Brodmann area.